One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2019-125485
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 7 |
Affiliation: Peter MacCallum Cancer Centre, Royal Melbourne Hospital, St Vincent's Hospital, University of Melbourne, Sir Charles Gairdner Hospital, University of Western Australia, Monash Health, Monash University, Third Affiliated Hospital of Harbin Medical University, Royal Hobart Hospital, Shanghai Institute of Hematology, Shanghai Jiao Tong University, UNSW Sydney, Epworth Hospital, Guangdong General Hospital, BeiGene (China), Concord Repatriation General Hospital, University of Sydney
An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
